Transcutaneous tibial nerve stimulation versus parasacral stimulation in the treatment of overactive bladder in elderly people: a triple-blinded randomized controlled trial

OBJECTIVES: To evaluate the effect of transcutaneous tibial nerve stimulation (TTNS) and transcutaneous parasacral stimulation on the treatment of overactive bladder (OAB) in elderly people and to compare the final results between groups. METHODS: Fifty female volunteers, mean age 68.62 (±5.9) years, were randomly allocated into two groups: those receiving TTNS (G1, N=25) and those receiving transcutaneous parasacral stimulation (G2, N=25). The primary outcome was the International Consultation on Incontinence Questionnaire (ICIQ-OAB) score, and secondary outcomes were the International Consultation on Incontinence Questionnaire - short form (ICIQ-SF) score and 3-day bladder diary measurements. Volunteers were assessed before and after the treatment. Clinical Trials (ReBeC): RBR-9Q7J7Y. RESULTS: Both groups' symptoms improved as measured by the ICIQ-OAB (G1 = <0.001; G2 = <0.001) and ICIQ-SF (G1 = <0.001; G2 = <0.001). In the 3-day bladder diary assessments after treatment, G1 showed a reduced number of nocturia (p<0.001), urgency (p<0.001) and urge urinary incontinence episodes (p<0.001), whereas G2 showed only a reduced number of nocturia episodes (p<0.001). No difference between groups was found. CONCLUSION: Both of the proposed treatments were effective in the improvement of OAB symptoms, but TTNS showed a reduction in a greater number of symptoms as measured by the 3-day bladder diary. No differences were found between groups.

Effects of the transobturator tape procedure on overactive bladder symptoms and quality of life: a prospective study

ABSTRACT Introduction: This study aimed to evaluate the effects of transobturator tape (TOT) on overactive bladder (OAB) symptoms and quality of life. Materials and Methods: Patients with stress-predominant mixed urinary incontinence (MUI) who had undergone TOT procedures were considered candidates for this research. Preoperative assessment included anamnesis, pelvic examination, cough stress test (CST), and validated symptom severity and quality of life (QoL) questionnaires. The primary outcome, improvement and cure rates of OAB symptoms were determined based on the patient's baseline scores in symptom-related questions in OAB-V8. Secondary outcomes included the success rates of SUI, changes in the QoL score and patient satisfaction rates. Results: A total of 104 patients were included in the study. Sixty-two patients underwent TOT placement alone, and 42 patients underwent TOT placement along with prolapse surgery. The mean follow-up period of the patients was 30.47 months range: 13-52 months. At the first-year follow-up, 52 patients (50.0%) and 59 patients (56.7%) reported cure in preoperative urgency and urgency incontinence, respectively. The objective and subjective cure rates were 96.2% and 56.7%, respectively. A total of 80.7% of the cases had a 15-point improvement in QoL scores. Conclusions: MUS is not only a gold standard treatment in SUI but also presents as a promising treatment modality in stress-dominant MUI. Although the improvement rates of OAB symptoms significantly decrease over time, QoL and patient satisfaction rates remain higher than any other treatment in this patient group at the third-year follow-up.

Lower urinary tract symptoms and sexual dysfunction in men with multiple sclerosis

OBJECTIVES: To assess the prevalence and interrelationship between lower urinary tract symptoms and sexual dysfunction in men with multiple sclerosis (MS). METHODS: In a cross-sectional study, we evaluated 41 men (mean age 41.1±9.9 years) with MS from February 2011 to March 2013, who were invited to participate irrespective of the presence of lower urinary tract symptoms or sexual dysfunction. Neurological impairment was assessed with the Expanded Disability Status Scale; lower urinary tract symptoms were evaluated with the International Continence Society male short-form questionnaire, and sexual dysfunction was evaluated with the International Index of Erectile Function. All patients underwent transabdominal urinary tract sonography and urine culture. RESULTS: The mean disease duration was 10.5±7.3 years. Neurological evaluation showed a median Expanded Disability Status Scale score of 3 [2-6]. The median International Continence Society male short-form questionnaire score was 17 [10-25]. The median International Index of Erectile Function score was 29 [15-46]. Twenty-nine patients (74.4%) had sexual dysfunction as defined by an International Index of Erectile Function score <45. Voiding dysfunction and sexual dysfunction increased with the degree of neurological impairment (r=0.02 [0.02 to 0.36] p=0.03 and r=-0.41 [-0.65 to -0.11] p=0.008, respectively). Lower urinary tract symptoms and sexual dysfunction also displayed a significant correlation (r=-0.31 [-0.56 to -0.01] p=0.04). CONCLUSIONS: Most male patients with MS have lower urinary tract symptoms and sexual dysfunction. The severity of the neurological disease is a predictive factor for the occurrence of voiding and sexual dysfunctions.

Prevalence of urodynamic changes with risk for upper urinary tract damage in neuroschistosomiasis patients

Abstract INTRODUCTION: This study aimed to identify the prevalence of urodynamic changes with an associated risk of developing upper urinary tract damage in neuroschistosomiasis patients. METHODS: A prospective study was conducted, wherein68 patients were admitted for analysis of urodynamics, urea and creatinine levels, and uroculture. RESULTS: Blood test results did not indicate kidney failure. There were cases of asymptomatic bacteriuria. Common symptoms were frequent nocturia and detrusor overactivity. Results of low compliance and low cystometric capacity were both statistically significant (p = 0.001 and p = 0.002, respectively). CONCLUSIONS: A high prevalence of negative urodynamic changes were found in neuroschistosomiasis patients.

Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

ABSTRACT Aim: To evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL). Methods: Case series with 10 patients with overactive bladder refractory to conservative treatment with anticholinergic or physical therapy. They received 200Ui of onabotulinumtoxin type A intravesically and were evaluated by overactive bladder symptoms score (OABSS) and King's Health Questionnaire. Results: The mean (SD) of the age was 52 + 14.5 years and 60% were female. All of them had confirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. The median and range of the OABSS was 13 (12-15) before therapy and decreased to 1.0 (0-12) on day 30 and to 03 (0-14) on day 90 (p < 0.0001). There was a significant improvement in 8 of the 9 domains of the King's Health Questionnaire after the intervention. Hematuria, urinary retention and urinary infection were the complications observed in 3 out of 10 patients. The mean time to request retreatment was 465 days. Conclusion: Onabotulinum toxin type A intravesically reduced the OABSS with last long effect and improved the quality of life of HTLV-1 infected patients with severe overactive bladder.

Pelvic floor muscle training for overactive bladder symptoms - A prospective study / Treinamento dos músculos do assoalho pélvico nos sintomas da bexiga hiperativa - Um estudo prospectivo

Summary Introduction: Pelvic floor muscle training (PFMT) involves the contraction of the puborectal, anal sphincter and external urethral muscles, inhibiting the detrusor contraction, what justify its use in the treatment of overactive bladder (OAB) symptoms. Objective: To verify the effects of isolated PFMT on the symptoms of OAB. Method: Prospective clinical trial with 27 women with mixed urinary incontinence (MUI), with predominance of OAB symptoms and loss ≥ 2 g in the pad test. It was evaluated: pelvic floor muscles (PFMs) function (digital palpation and manometry); urinary symptoms (nocturia, frequency and urinary loss); degree of discomfort of OAB symptoms; and quality of life (Incontinence Quality-of-Life Questionnaire [I-QoL]). The PFMT program consisted of 24 outpatient sessions (2x/week + home PFMT). The Mann-Whitney and Wilcoxon tests (with a significance level of 5%) were used to analyse the data. Results: There was a significant improvement of the urinary symptoms to the pad test (5.8±9.7, p<0.001), urinary loss (0.7±1.1, p=0.005) and nocturia (0.8±0.9, p=0.011). Reduction in the degree of discomfort of urinary symptoms was observed according to OAB-V8 questionnaire (10.0±7.7, p=0.001). There were also significant results in PFMs function: Oxford (3.6±0.9, p=0.001), endurance (5.2±1.8, p<0.001), fast (8.9±1.5, p<0.001) and manometry (26.6±15.8, p=0.003). In addition, quality of life had a significant improvement in the three domains evaluated by I-QoL. Conclusion: The PFMT without any additional guidelines improves the symptomatology, the function of PFMs and the quality of life of women with OAB symptoms.

Resumo Introdução: O treinamento dos músculos do assoalho pélvico (TMAP) envolve a contração dos músculos puborretal, esfíncteres anal e uretral externo, inibindo a contração do detrusor, o que justifica sua utilização no tratamento dos sintomas da bexiga hiperativa (BH). Objetivo: Verificar os efeitos do TMAP isolado sobre a sintomatologia da BH. Método: Ensaio clínico prospectivo com 27 mulheres com incontinência urinária mista (IUM), com predomínio de sintomas de BH e perda ≥ 2 g no pad test. Avaliaram-se: função dos músculos do assoalho pélvico (MAP) (palpação digital e manometria); sintomas urinários (noctúria, frequência e perda urinária); grau de incômodo dos sintomas de BH (Overactive Bladder Questionnaire [OAB-V8]); e qualidade de vida (Incontinence Quality-of-Life Questionnaire [I-QoL]). O programa de TMAP consistiu em 24 sessões ambulatoriais (2x/semana + TMAP domiciliar). Os testes de Mann-Whitney e Wilcoxon (com nível de significância de 5%) foram utilizados para analisar os dados. Resultados: Observou-se melhora significativa dos sintomas urinários ao pad test (5,8±9,7; p<0,001); ao diário miccional (perda urinária [0,7±1,1; p=0,005] e noctúria [0,8±0,9; p=0,011]). Foram observados redução do grau de incômodo dos sintomas urinários conforme questionário OAB-V8 (10,0±7,7; p=0,001) e significativos resultados na função dos MAP: Oxford (3,6±0,9; p=0,001), Endurance (5,2±1,8; p<0,001), Fast (8,9±1,5; p<0,001) e manometria (26,6±15,8; p=0,003). No mais, a qualidade de vida teve significativa melhora nos três domínios avaliados pelo I-QoL. Conclusão: O TMAP sem quaisquer orientações adicionais melhora a sintomatologia, a função dos MAP e a qualidade de vida de mulheres com sintomas de BH.

Factors associated with overactive bladder syndrome in the elderly community: a cross-sectional study / Fatores associados à síndrome da bexiga hiperativa em idosas: um estudo transversal

Abstract Objective: to identify risk factors related to overactive bladder syndrome. Method: a cross-sectional study was performed with elderly women (>60 years) from the community of Ceilândia, in the Distrito Federal, Brazil, with or without symptoms of OBS, who were evaluated through interviews and questionnaires. The clinical and sociodemographic variables analyzed were: age; body mass index (BMI); parity, schooling, previous abdominal and urogynecologic surgeries, physical activity, smoking, constipation, systemic arterial hypertension (SAH), diabetes mellitus; depression and anxiety. The questionnaires applied were the Overactive Bladder Awareness Tool (OAB-V8), the Geriatric Depression Scale and the Beck Anxiety Scale. Data were analyzed descriptively. Binary logistic regression was used to evaluate the significant associations between the independent variables and the outcome of interest. Risk ratios were calculated for each independent variable with 95% confidence intervals. Result: A total of 372 volunteers were recruited, 292 of whom were eligible. Of these, 172 were allocated to the case group (58.9%) and 120 (41.1%) were control subjects. The two groups were homogeneous between one another. There was a high prevalence of OBS in the study population and significant differences for the variables presence of SAH, abdominal surgery and pelvic surgery, with the case group presenting a higher frequency of these events. In multivariate analysis, it was observed that an active sexual life reduces the chance of having OBS by 70.8%, while urogynecologic surgeries increase this risk 3.098 times. Conclusion: In univariate logistic regression analysis, BMI, SAH, a previous history of abdominal and urogynecologic surgery, number of abortions and the presence of symptoms of depression and anxiety, were found to be factors associated with OBS. AU

Resumo Objetivo: Identificar os fatores clínicos e sociodemográficos associados à Síndrome da Bexiga Hiperativa (SBH). Método: Estudo transversal, realizado com idosas (>60 anos) da comunidade de Ceilândia, DF, Brasil; avaliadas por meio de entrevistas e questionários. As variáveis clínicas e sociodemográficas analisadas foram: idade; índice de massa corpórea (IMC); paridade, escolaridade, cirurgias abdominais e uroginecológicas prévias, prática de atividade física, tabagismo, constipação, hipertensão arterial sistêmica (HAS), diabetes mellitus; depressão e ansiedade. Os questionários aplicados foram Overactive Bladder Awerenees Tool (OAB-V8), Escala de Depressão Geriátrica e Escala de Ansiedade de Beck. Os dados foram analisados descritivamente. Utilizou-se a regressão logística binária para avaliar as associações significativas entre as variáveis independentes e o desfecho de interesse. As razões de risco foram calculadas para cada variável independente com intervalos de 95% de confiança. Resultados: Recrutou-se 372 voluntárias, sendo elegíveis 292, destas, 172 eram grupo caso (58,9%) e 120 (41,1%) eram grupo controle. Observou-se alta prevalência de SBH na população estudada, além de diferenças significativas para as variáveis: presença de HAS; ter realizado cirurgia abdominal ou cirurgia pélvica, sendo que o grupo caso apresentou maior frequência desses eventos. Na análise multivariada, observou-se que vida sexual ativa reduz em 70,8% a chance de ter SBH, e cirurgias uroginecológicas aumentam em 3,098 vezes esse risco. Conclusão: Na análise de regressão logística univariada, o IMC, a HAS, a história prévia de cirurgia abdominal e uroginecológica, quantidade de abortos, presença de sintomas de depressão e ansiedade, apresentaram-se como fatores associados à SBH. AU

Correlation between overactive bladder symptom score and neuropsychological parameters in Alzheimer's disease patients with lower urinary tract symptom

ABSTRACT Purpose To examine an association between the overactive bladder symptom score (OABSS) and neuropsychological parameters. Moreover, we investigate the factors that affect each item in the questionnaire. Materials and Methods A total of 376 patients (males: 184; females: 192) with probable Alzheimer’s disease (AD) were recruited. Cognitive testing was conducted using the Mini Mental Status Examination (MMSE), Clinical Dementia Rating (CDR) scale, Global Deterioration Scale (GDS), and Barthel Activities of Daily Living (ADL). Lower urinary tract symptom (LUTS) was assessed using OABSS and voiding diary. Results The prevalence of overactive bladder (OAB) (defined as OABSS ≥3 with an urgency score of ≥2) in patients with AD was 72.6%. Among the OAB subjects, the most common severity of symptom was moderate (72.6%), followed by mild (21.2%), and severe (5.8%). It was found that OABSS had a very high correlation with aging (r=0.75; p<0.001). When compared with neuropsychological parameters, it was found that OABSS was highly correlated with the CDR scores (r=0.446; p<0.001). However, no significant correlation was found between the changes in OABSS scores and those in other neuropsychological parameters. Based on the individual symptom scores, urgency incontinence was highly correlated with the CDR scores (r=0.43; p<0.001). Conclusions OABSS is a useful tool in assessing AD patients with LUTS. There was a consistent positive association between OABSS severity, including urgency incontinence, and CDR scores.

Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study

ABSTRACT Introduction This study compared percutaneous tibial nerve stimulation (PTNS) versus electrical stimulation with pelvic floor muscle training (ES + PFMT) in women with overactive bladder syndrome (OAB). Materials and Methods 60 women with OAB were enrolled. Patients were randomized into two groups. In group A, women underwent ES with PFMT, in group B women underwent PTNS. Results A statistically significant reduction in the number of daily micturitions, episodes of nocturia and urge incontinence was found in the two groups but the difference was more substantial in women treated with PTNS; voided volume increased in both groups. Quality of life improved in both groups, whereas patient perception of urgency improved only in women treated with PTNS. Global impression of improvement revealed a greater satisfaction in patients treated with PTNS. Conclusion This study demonstrates the effectiveness of PTNS and ES with PFMT in women with OAB, but greater improvements were found with PTNS.

Optimal bladder diary duration for patients with suprapontine neurogenic lower urinary tract dysfunction

ABSTRACT Purpose: To identify the minimum bladder diary's length required to furnish reliable documentation of LUTS in a specific cohort of patients suffering from neurogenic urinary dysfunction secondary to suprapontine pathology. Materials and Methods: From January 2008 to January 2014, patients suffering from suprapontine pathology and LUTS were requested to prospectively complete a bladder diary form for 7 consecutive days. Micturitions per day, excreta per micturition, urgency and incontinence episodes and voided volume per day were evaluated from the completed diaries. We compared the averaged records of consecutive days (2-6 days) to the total 7 days records for each patient's diary, seeking the minimum diary's length that could provide records comparable to the 7 days average, the reference point in terms of reliability. Results: From 285 subjects, 94 male and 69 female patients enrolled in the study. The records of day 1 were significantly different from the average of the 7 days records in every parameter, showing relatively small correlation and providing insufficient documentation. Correlations gradually increased along the increase in diary's duration. According to our results a 3-day duration bladder diary is efficient and can provide results comparable to a 7 day length for four of our evaluated parameters. Regarding incontinence episodes, 3 days seems inadequate to furnish comparable results, showing a borderline difference. Conclusions: A 3-day diary can be used, as its reliability is efficient regarding number of micturition per day, excreta per micturition, episodes of urgency and voided volume per day.

Evaluation of female overactive bladder using urodynamics: relationship with female voiding dysfunction

ABSTRACTPurpose:To investigate the role of urodynamic study (UDS) in female patients with overactive bladder (OAB) analyzing the relationship between OAB symptoms and female voiding dysfunction (FVD).Materials and Methods:We analyzed the clinical and urodynamic data of 163 women with OAB symptoms. OAB symptoms were categorized as dry and wet. FVD was described as detrusor underactivity (DUA), which was defined as a maximum flow rate (Qmax) of ≤15mL/s associated with a detrusor pressure at Qmax (PdetQmax) of ≤20cmH2O, along with bladder outlet obstruction (BOO), which was defined as a Qmax of ≤15mL/s with a PdetQmax of >20cmH2O. Clinical and urodynamic results were compared between patients with dry and wet symptoms and between those with and without FVD.Results:78 (47.9%) had dry, and 85 (52.1%) had wet symptoms. The entire group had a relatively low Qmax (15.1±6.6mL/s) and relatively high number of BOO (42.9%, 70/163) and DUA (8.6%, 14/163). A significantly higher number of patients with wet symptoms had detrusor overactivity compared to those with dry, as detected by the UDS (p<0.05). No significant differences were found in BOO and DUA number between dry and wet groups. Further, the international prostate symptom score did not different significantly between patients with and without FVD.Conclusion:A significant number of women with OAB had voiding dysfunction. However, the OAB symptoms themselves were not useful for predicting the presence of FVD. Therefore, UDS may be necessary for accurate diagnosis in women with OAB symptoms.

Association between urinary symptoms and quality of life in HTLV-1 infected subjects without myelopathy

Objective To investigate the relationship between urinary symptoms and quality of life of patients infected with HTLV-1. Materials and Methods This is a cross-sectional study that enrolled individuals with HTLV-1 positive serology from February 2010 to March 2011. Participants were HTLV-1 infected subjects followed in the HTLV-1 clinic of the University Hospital in Salvador, Bahia, Brazil. Patients with HTLV-1 associated myelopathy / tropical spastic paraparesis (HAM/TSP), who had evidence of other neurological diseases, diabetes mellitus or were pregnant were excluded from the study. The questionnaire SF-36 was used to evaluate quality of life and the questionnaire OAB-V8 was used to evaluate urinary symptoms. Results From the 118 individuals evaluated, 50 (42.4%) complained of urinary symptoms and 68 (57.6%) did not. Most participants were females. There was no difference between the groups regarding demographic variables. The group with symptoms showed significantly lower scores in all domains of the SF-36 questionnaire. The domains with greatest differences were vitality and general health state. Conclusions Urinary symptoms negatively influence the quality of life of individuals infected with HTLV-1. .

Neurological symptoms and signs in HTLV-1 patients with overactive bladder syndrome / Sinais e sintomas neurológicos em pacientes com HTLV-1 e síndrome de bexiga hiperativa

OBJECTIVE: To compare neurological symptoms and signs in HTLV-1 asymptomatic carriers and HTLV-1 patients with overactive bladder (OB) syndrome. METHODS: We studied 102 HTLV-1 positive individuals without HAM/TSP (HTLV-1 associated myelopathy/tropical spastic paraparesis) divided into two groups according to the presence or absence of OB syndrome. Clinical interview, neurological exam and proviral load was performed in all patients. RESULTS AND CONCLUSIONS: Individuals with OB were more commonly female (84.3 vs. 60.8% of asymptomatics, p=0.01). The prevalence of neurological complaints was higher in OB group, especially hand or foot numbness and arm or leg weakness. There was no difference between the groups in neurological strength and reflexes. Weakness complaint remained strongly associated with OB in multivariate logistic regression analysis adjusting for sex and age [adjusted odds ratio and 95%CI 3.59 (1.45-8.88) in arms and 6.68 (2.63-16.93) in legs]. Proviral load was also different between the two groups with higher level on OB individuals.

OBJETIVO: Comparar sintomas e sinais neurológicos em pacientes portadores do HTLV-1 assintomáticos e com síndrome de bexiga hiperativa (BH). MÉTODOS: Foram estudados 102 indivíduos com HTLV-1 sem HAM/TSP (mielopatia associada ao HTLV-I/paraparesia espástica tropical), divididos em dois grupos segundo a presença ou ausência de BH. Foram realizados em todos os pacientes entrevista clínica, exame neurológico e carga proviral. RESULTADOS E CONCLUSÕES: Indivíduos com BH foram na maioria do sexo feminino (84,3 vs. 60,8% dos assintomáticos, p=0,01). A prevalência de queixas neurológicas foi maior no grupo BH, especialmente dormências e fraqueza em extremidades. Não houve diferença entre os grupos em relação a achados do exame neurológico. Fraqueza subjetiva permaneceu fortemente associada com BH na regressão logística multivariada ajustada para sexo e idade [OR e IC95% 3,59 (1,45-8,88) nos braços e 6,68 (2,63-16,93) nas pernas]. A carga proviral foi também diferente entre os dois grupos com nível maior em indivíduos com BH.

Toxina botulínica tipo A, apresentação de 200 U, para o tratamento da bexiga hiperativa / Botulinum toxin type A, presentation of 200 U, for the treatment of overactive bladder

A DOENÇA: A síndrome da bexiga hiperativa, síndrome de urgência ou síndrome de urgência-freqüência caracteriza-se pela presença de urgência miccional, com ou sem urge-incontinência, usualmente acompanhada de noctúria e aumento da freqüência urinária, na ausência de fatores infecciosos, metabólicos ou locais. A Síndrome costuma comprometer sobremaneira a qualidade de vida, sendo causa de isolamento social, frustração e ansiedade. A bexiga hiperativa pode ser decorrente alguma doença, de uma lesão ou de uma alteração congênita que afeta o cérebro, a medula espinhal ou os nervos que se dirigem à bexiga, seu esfíncter ou a ambos. É uma disfunção que atinge cerca de 16,5% da população adulta, de ambos os gêneros. O tratamento clínico farmacológico da bexiga hiperativa inclui, principalmente, a utilização de anticolinérgicos. O tratamento clínico não farmacológico inclui as medidas gerais, tratamento comportamental, fisioterapêutico e o cateterismo intermitente. A TECNOLOGIA: Toxina Botulínica Tipo A1 - Indicação aprovada na Anvisa: -Tratamento de estrabismo e blefarospasmo associado com distonia, incluindo blefarospasmo essencial benigno ou distúrbios do VII par craniano em pacientes com idade acima de 12 anos; -Tratamento de distonia cervical; -Tratamento de espasmo hemifacial; -Tratamento de espasticidade muscular; -Tratamento de linhas faciais hipercinéticas; -Tratamento de hiperidrose focal palmar e axilar; -Tratamento de incontinência urinária causada por hiperatividade neurogênica do músculo detrusor da bexiga, não tratada adequadamente por anticolinérgicos; -Profilaxia em adultos de migrânea crônica* - enxaquecas crônicas e refratárias com comprometimento importante da qualidade de vida e das atividades diárias (laborativas, sociais, familiares e de lazer) o termo "enxaqueca" e "migrânea" são sinônimos. Indicação proposta: alternativa para o tratamento da bexiga neurogênica (hiperativa) após o efeito negativo na qualidade de vida dos efeitos adversos do tratamento com anticolinérgicos orais e/ou abandono com esta terapêutica. EVIDÊNCIAS CIENTÍFICAS: Além da análise dos estudos apresentados pelo demandante, a Secretaria-Executiva da CONITEC realizou busca na literatura por artigos científicos, com o objetivo de encontrar Revisões Sistemáticas e Ensaios Clínicos Randomizados (ECR), estudos que são considerados a melhor evidência para avaliar a eficácia de uma tecnologia usada para tratamento. As bases pesquisadas foram Medline (via PubMed), The Cochrane Library (via Bireme) e CRD (Centre for Reviews and Dissemination). Os termos utilizados na busca foram "toxinum botulinum type a", "urinary incontinence", "neurogenic detrusor overactivity". Foram considerados os estudos publicados até o dia 19/06/2012, nos idiomas inglês, português ou espanhol. CONSIDERAÇÕES FINAIS: A evidência atualmente disponível sobre a eficácia da toxina botulínica para o tratamento da bexiga hiperativa é de nível 1A, maior nível de evidência. O benefício do medicamento foi observado em revisão sistemática, embora ainda haja poucos estudos randomizados acerca da eficácia deste medicamento para o tratamento da bexiga hiperativa. DELIBERAÇÃO FINAL: Os membros da CONITEC presentes na 7ª reunião ordinária do dia 02/08/2012, por unanimidade, deliberaram por recomendar a não incorporação do medicamento Botox® para o tratamento da bexiga hiperativa. No entanto, recomendaram a elaboração de Protocolo Clínico e Diretrizes Terapêuticas dessa condição, englobando a terapêutica clínica e cirúrgica. DECISÃO: PORTARIA Nº40, de 27 de setembro de 2012 - Torna pública a decisão de não incorporar o medicamento Botox® para o tratamento da bexiga hiperativa no Sistema Único de Saúde (SUS) e recomendar a elaboração de Protocolo Clínico e Diretrizes Terapêuticas dessa condição, englobando a terapêutica clinica e cirúrgica.

Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity

Purpose: To report our experience with the use of the botulinum toxin-A (BoNT/A) formulations Botox® and Prosigne® in the treatment of neurogenic detrusor overactivity (NDO). Materials and methods: At a single institution, 45 consecutive patients with refractory urinary incontinence due to NDO received a single intradetrusor (excluding the trigone) treatment with botulinum toxin type A 200 or 300 units. Botox was used for the first 22 patients, and Prosigne for the subsequent 23 patients. Evaluations at baseline and week 12 included assessment of continence and urodynamics. Safety evaluations included monitoring of vital signs, hematuria during the procedure, hospital stay, and spontaneous adverse event reports. Results: A total of 42 patients were evaluated (74 percent male; mean age, 34.8 years). Significant improvements from baseline in maximum cystometric capacity (MCC), maximum detrusor pressure during bladder contraction, and compliance were observed in both groups (P < 0.05). Improvement in MCC was significantly greater with Botox versus Prosigne (+103.3 percent vs. +42.2 percent; P = 0.019). Continence was achieved by week 12 in 16 Botox recipients (76.2 percent) and 10 Prosigne recipients (47.6 percent; P = 0.057). No severe adverse events were observed. Mild adverse events included 2 cases of transient hematuria on the first postoperative day (no specific treatment required), and 3 cases of afebrile urinary tract infection. Conclusions: Botox and Prosigne produce distinct effects in patients with NDO, with a greater increase in MCC with Botox. Further evaluation will be required to assess differences between these formulations.

Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals

OBJECTIVE:To describe urodynamic abnormalities in HTLV-1 infected individuals presenting urinary symptoms and verify if these findings and quality of life (QOL) evaluation correlate with overall neurological impairment. MATERIALS AND METHODS: From January/2001 to May/2004, 324 HTLV-1 seropositive subjects were evaluated to determine the occurrence of urinary symptoms. Urodynamic testing was performed in those who complained of frequency, urgency, or incontinence. They went through a complete clinical, neurological, and urological examination to investigate symptoms and signs of myelopathy. Neurological disability was assessed by Expanded Disability Status Scale (EDSS). RESULTS: From the 324 patients evaluated, 78 underwent the urodynamic testing. Fifty-seven individuals were females (73.1 percent) and age ranged from 23 to 76 years (mean = 48.7 years; SD ± 11.6). Urodynamic testing was abnormal in 63 patients (80.8 percent). The major abnormality was detrusor overactivity (DO), observed in 33 individuals (33/63; 52.4 percent), followed by detrusor-external sphincter dyssynergia (DESD), diagnosed in 15 subjects (15/63; 25.4 percent). HAM/TSP patients had significantly more DESD than the HTLV-I carriers (p = 0.005; OR = 5.5; CI: 1.6 to 19.4). QOL was severely compromised in HAM/TSP patients. CONCLUSIONS: Prominent urodynamic abnormalities were identified in individuals genuinely considered as HTLV-I carriers, suggesting an early compromise of the urinary tract; whereas HAM/TSP patients presented urodynamic findings, which posed a potential risk to the upper urinary tract (dyssynergia). Urodynamic evaluation should be performed in all HTLV-I-infected individuals with voiding complaints.

Evaluación vesical urodinámica en pacientes con insuficiencia renal crónica en etapa avanzada / Urodynamics evaluation in patiens with end-stage renal disease

Introducción: La Insuficiencia Renal Crónica en etapa avanzada es una condición incompatible con la vida. En la actualidad los diversos tipos de sustitución de la función renal (Diálisis) permiten la vida de estos pacientes, sin embargo, su calidad de vida se ve deteriorada. El tratamiento definitivo de la enfermedad es el trasplante renal. Sin embargo, para que este procedimiento sea efectivo, es necesario contar con múltiples condiciones, entre ellas una vejiga que cumpla completamente con su función original, la cual puede estar comprometida con el paso de los años en que cesa la producción de orina (Anuria). Pacientes y método: Se diseñó estudio prospectivo, de diciembre de 2004 a diciembre 2005, que evalúa a los pacientes en anuria, referidos desde policlínico de nefrología para estudio pretrasplante mediante Urodinamia y Cistoscopía, con el fin de evidenciar los cambios experimentados por la vejiga. Resultados: Durante diciembre de 2004 y diciembre de 2005 se estudiaron 29 pacientes en anuria, 16 pacientes desexo femenino y 13 varones, el 45 por ciento diabéticos, el 72 por ciento con menos de 10 años de Insuficiencia Renal Crónica y 90 por ciento con menos de 10 años en diálisis. De los hallazgos en la urodinamia, 62,1 por ciento presentaban una Hiperactividad Idiopática del Detrusor y un 48 por ciento una disminución en la Acomodación Vesical. Conclusión: Concluimos que existen cambios funcionales en la vejiga que se ve sometida a una disminución en la producción de orina durante el tiempo, y que no existe la necesidad de realizar estudios urodinámicos en todos los pacientes en espera de trasplante. Sin embargo, existen ciertas condiciones en las que debe realizarse como rutina. Los resultados concuerdan con la bibliografía revisada, donde se observa que, conforme disminuye la producción de orina diaria, existe disminución en la Capacidad Vesical, en la Acomodación Vesical, y un aumento en la Hiperactividad del Detrusor.

Introduction: The End-Stage Renal Disease is a life incompatible condition. Nowadays, dialysis allows patients to live with a limited complications rate, nevertheless, quality of life is diminished in this population. Renal transplant (RT) constitutes a feasible and reliable treatment for patients with renal failure patients. Multiple conditions should be preoperatively evaluated in renal transplant patients. Bladder function remains an important factor to asses in preoperatory evaluations of kidney recipients. Patients and Methods: Between December 2004 and December 2005, 29 nine kidney receptors wereprospectively evaluated with cystoscopy and urodynamics. The aim of the study was to assess bladder functional changes induced by anury in this cohort. Results: The population of the study was composed by 29 patients, 16 female and 13 male. Forty five percent of patients' harbored diabetes mellitus, 72 percent had less than 10 years with End Stage Renal Disease and 90 percent had less than 10 years in dialysis. Urodynamic evaluation evidenced 62 percent of overactive bladder and 48 percent diminution in bladder compliance. Conclusion: Bladder functional changes are verified in patients in anury due to renal failure. These conditions might influence preoperative evaluation of patients undergoing RT. The most important variations verified in bladder function are diminution in bladder capacity and compliance, and increase of detrusor activity.